Diligence memo · auto-generated · as of July 2, 2026
Time Therapeutics Inc.
Time Therapeutics Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Time Therapeutics Inc. operates in Pharma, based in New York.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Time Therapeutics Inc. has raised $29M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $13M on 2024-06-20.
Most recent recorded round closed around 2024-06-20.
Valuation (modeled)modeled
Provath models Time Therapeutics Inc. at approximately $67M (range $15M–$146M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.98× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era. Within the normal band (98% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 2.0 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 80% of Pharma peers (310 compared).
Modeled value ranks above 59% of those peers.
Closest niche peers: Carmine Therapeutics, Inc., Triomics, Inc., Spiral Therapeutics Inc, Convelo Therapeutics, Inc., ADvantage Therapeutics, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.